Anneli Savinainen

Vice President & Head of Preclinical Development Mariana Oncology

Accomplished biopharmaceutical executive with deep expertise in preclinical research and development, Anneli Savinainen leads the advancement of innovative therapies from discovery through IND-enabling studies into early clinical development. As Vice President and Head of Preclinical Development at Mariana Oncology (a Novartis company), she directs multidisciplinary teams spanning pharmacology, toxicology, DMPK/ADME, and imaging, with a particular focus on precision radioligand therapies (RLTs). She has a strong track record of successful IND submissions across diverse modalities, including targeted oncology programs.

Anneli has held leadership and scientific roles at Mariana Oncology, Aura Biosciences, Syros Pharmaceuticals, Shire, EMD Serono, Resolvyx Pharmaceuticals, Millennium Pharmaceuticals, and AstraZeneca. She holds a Master of Science in Pharmacology and a Graduate Certificate in Clinical Trial Design and Project Management from Northeastern University, and a Bachelor of Science in Medical Laboratory Sciences from the University of Gothenburg. She is known for building high-performing teams, driving cross-functional collaboration, and delivering high-quality data to enable clinical success.

Seminars

Wednesday 24th February 2027
Optimizing a DLL3-Targeted Radiotherapeutic Through Preclinical Development
3:00 pm
  • Explore the preclinical development of a DLL3-targeted radiotherapeutic from candidate design through efficacy evaluation
  • Assess how biodistribution, tumor uptake & retention inform optimization of radiotherapeutic performance
  • Leverage preclinical findings to guide candidate selection & progression towards clinical development

Novel Target

Thursday 25th February 2027
Fireside Chat: How Much Preclinical Evidence Is Enough?: Defining a Fit-for-Purpose Preclinical Package to Progress RLTs Towards IND
10:00 am
  • Benchmark contrasting approaches to preclinical development to determine the level of evidence required to progress confidently towards the clinic
  • Determine which studies generate decision-critical evidence versus where additional data adds time, cost, & complexity without strengthening the development case
  • Balance toxicology, biodistribution, dosimetry, pharmacology, & model selection to build a robust package proportionate to the candidate and development stage
  • Leverage early FDA engagement to clarify expectations, ask the right scientific questions, & establish a more predictable path towards IND
Anneli Savinainen, Speaker at 3rd TRP Target Selection & Drug Design Summit